Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland.

Aims: Indacaterol/glycopyrronium (IND/GLY) 110/50 μg is a once-daily (o.d.) fixed-dose combination of long-acting β-agonist/long-acting muscarinic antagonist approved in over 90 countries, including Ireland, for the management of COPD.